Therapeutic Effects of Extinction Learning as a Model of Exposure Therapy in Rats

Neuropsychopharmacology

Volumn 41, Issue 13, 2016, Pages 3092-3102

  Fucich, Elizabeth A ^a   Paredes, Denisse ^a   Morilak, David A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S6; ANISOMYCIN; PROTEIN C FOS; PROTEIN SYNTHESIS INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC STRESS; CHRONIC UNPREDICTABLE STRESS; CONDITIONING; CONTROLLED STUDY; COPING BEHAVIOR; DEFENSIVE BURYING TEST; DEPRESSION; ENVIRONMENTAL ENRICHMENT; EXPOSURE THERAPY; FEAR CONDITIONING TEST; FOOTSHOCK; HABITUATION; LEARNING; MALE; MEDIAL PREFRONTAL CORTEX; NEUROBIOLOGY; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; THERAPY EFFECT; ANIMAL; ASSOCIATION; ATTENTION; BRAIN; DISEASE MODEL; ELECTROSHOCK; FEAR; IMPLOSIVE THERAPY; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PROCEDURES; REHABILITATION; REINFORCEMENT; SPRAGUE DAWLEY RAT;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; ANISOMYCIN; ASSOCIATION LEARNING; ATTENTION; BRAIN; CONDITIONING (PSYCHOLOGY); CUES; DISEASE MODELS, ANIMAL; ELECTROSHOCK; EXTINCTION, PSYCHOLOGICAL; FEAR; IMPLOSIVE THERAPY; MALE; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6; STRESS, PSYCHOLOGICAL;

EID: 84981156645     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.127     Document Type: Article

References (52)

1. Beck AT (1976). Cognitive Therapy and the Emotional Disorders. Int. Univ. Press: New York.
2. Beck AT (2005). The current state of cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry 62: 953-959.
3. Biehn TL, Contractor A, Elhai JD, Tamburrino M, Fine TH, Prescott MR et al (2013). Relations between the underlying dimensions of PTSD and major depression using an epidemiological survey of deployed Ohio National Guard soldiers. J Affective Disord 144: 106-111.
4. Biever A, Valjent E, Puighermanal E (2015). Ribosomal protein S6 phosphorylation in the nervous system: From regulation to function. Front Mol Neurosci 8: 75.
5. Birrell JM, Brown VJ (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20: 4320-4324.
6. Bondi CO, Barrera G, Lapiz MDS, Bédard T, Mahan A, Morilak DA. (2007). Noradrenergic facilitation of shock-probe defensive burying in lateral septum of rats, modulation by chronic treatment with desipramine. Prog Neuropsychopharmacol Biol Psychiatry 31: 482-495.
7. Bondi CO, Jett JD, Morilak DA (2010). Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated by alpha1-adrenergic receptors in medial prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 34: 913-923.
8. Bondi CO, Rodriguez G, Gould GG, Frazer A, Morilak DA (2008). Chronic unpredictable stress induces a cognitive deficit and anxietylike behavior in rats that is prevented by chronic antidepressant drug treatment. Neuropsychopharmacology 33: 320-331.
9. Brewin CR (1996). Theoretical foundations of cognitivebehavior therapy for anxiety and depression. Annu Rev Psychol 47: 33-57.
10. Bryant RA, Kenny L, Joscelyne A, Rawson N, Maccallum F, Cahill C et al (2014). Treating prolonged grief disorder: a randomized clinical trial. JAMA Psychiatry 71: 1332-1339.
11. Buffington SA, Huang W, Costa-Mattioli M (2014). Translational control in synaptic plasticity and cognitive dysfunction. Annu Rev Neurosci 37: 17-38.
12. Coles ME, Heimberg RG (2002). Memory biases in the anxiety disorders: current status. Clin Psychol Rev 22: 587-627.
13. de Kleine RA, Rothbaum BO, van Minnen A (2013). Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review. Eur J Psychotraumatol 4: 21626.
14. Donegan JJ, Patton MS, Chavera TA, Berg KA, Morilak DA, Girotti M et al (2015). Interleukin-6 attenuates serotonin2A receptor signaling by activating the JAK-STAT pathway. Mol Pharmacol 87: 492-500.
15. Drevets WC (2000). Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126: 413-431.
16. Duman RS, Li N, Liu R-J, Duric V, Aghajanian G (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35-41.
17. Elhai JD, Carvalho LF, Miguel FK, Palmieri PA, Primi R, Christopher Frueh B (2011). Testing whether posttraumatic stress disorder and major depressive disorder are similar or unique constructs. J Anxiety Disord 25: 404-410.
18. Elzinga BM, Bremner JD (2002). Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD) J Affect Disord 70: 1-17.
19. Foa EB, Meadows EA (1997). Psychosocial treatments for posttraumatic stress disorder: a critical review. Ann Rev Psychol 48: 449-480.
20. Green MK, Rani CSS, Joshi A, Soto-Pinã AE, Martinez PA, Frazer A et al (2011). Prenatal stress induces long term stress vulnerability, compromising stress response systems in the brain and impairing extinction of conditioned fear after adult stress. Neuroscience 192: 438-451.
21. Hayes AM, Beevers CG, Feldman GC, Laurenceau JP, Perlman C (2005). Avoidance and processing as predictors of symptom change and positive growth in an integrative therapy for depression. Int J Behav Med 12: 111-122.
22. Hoffmann SG (2008). Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clin Psychol Rev 28: 199-210.
23. Hollon SD, Thase ME, Markowitz JC (2002). Treatment and prevention of depression. Psychol Sci Public Interest 3: 39-77.
24. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Treatment with antidepressants. In: Janicak PG, Davis JM, Preskorn SH, Ayd FJ (eds). Principles and Practice of Psychopharmacotherapy, 2nd edn. Williams & Wilkins: Baltimore, 1997, pp 243-356.
25. Jett JD, Boley AM, Girotti M, Shah A, Lodge DJ, Morilak DA (2015). Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology 232: 3123-3133.
26. Jett JD, Morilak DA (2013). Too much of a good thing: blocking noradrenergic facilitation in medial prefrontal cortex prevents the detrimental effects of chronic stress on cognition. Neuropsychopharmacology 38: 585-595.
27. Knight ZA, Tan K, Birsoy K, Schmidt S, Garrison JL, Wysocki RW et al (2012). Molecular profiling of activated neurons by phosphorylated ribosome capture. Cell 151: 1126-1137.
28. Koolhaas JM, Korte SM, De Boer SF, Van der Vegt BJ, Van Reenen CG, Hopster H et al (1999). Coping styles in animals: current status in behavior and stress-physiology. Neurosci Biobehav Rev 23: 925-935.
29. Lapiz MDS, Morilak DA (2006). Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137: 1039-1049.
30. Mathews A, Mackintosh B (1998). A cognitive model of selective processing in anxiety. Cognit Ther Res 22: 539-560.
31. McLean CP, Foa EB (2013). Dissemination and implementation of prolonged exposure therapy for posttraumatic stress disorder. J Anxiety Disord 27: 788-792.
32. McNally RJ (2007). Mechanisms of exposure therapy: how neuroscience can improve psychological treatments for anxiety disorders. Clin Psychol Rev 27: 750-759.
33. Mueller D, Porter JT, Quirk GJ (2008). Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 28: 369-375.
34. Nemeroff CB, Helm CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF et al (2003). Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 100: 14293-14296.
35. Nutt DJ (2010). Rationale for, barriers to, appropriate medication for the long-term treatment of depression. J Clin Psychiatry 71: e02.
36. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: San Diego, 1986.
37. Quirk GJ, Garcia R, González-Lima F (2006). Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry 60: 337-343.
38. Richter JD, Klann E (2009). Making synaptic plasticity and memory last: mechanisms of translational regulation. Genes Dev 23: 1-11.
39. Ritchey M, Dolcos F, Eddington KM, Strauman TJ, Cabeza R (2011). Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response. J Psychiatr Res 45: 577-587.
40. Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K et al (2004). Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 50: 1-11.
41. Rosenblum K, Meiri N, Dudai Y (1993). Taste memory: the role of protein synthesis in gustatory cortex. Behav Neural Biol 59: 49-56.
42. Roth MK, Bingham B, Shah A, Joshi A, Frazer A, Strong R et al (2012). Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, evoked HPA-axis reactivity. Neuropharmacology 63: 1118-1126.
43. Santini E, Ge H, Ren K, Penã de Ortiz S, Quirk GJ (2004). Consolidation of fear extinction requires protein synthesis in the medial prefrontal cortex. J Neurosci 24: 5704-5710.
44. Shah AA, Sjuvold T, Treit D (2004). Inactivation of the medial prefrontal cortex with the GABAA receptor agonist muscimol increases open-arm activity in the elevated plus-maze and attenuates shock-probe burying in rats. Brain Res 1028: 112-115.
45. Sheehan TP, Chambers RA, Russel DS (2004). Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res Rev 46: 71-117.
46. Sheline YI (2003). Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54: 338-352.
47. Sotres-Bayon F, Bush DE, LeDoux JE (2004). Emotional perseveration: an update on prefrontal-amygdala interactions in fear extinction. Learn Mem 11: 525-535.
48. Straub J, Plener PL, Sproeber N, Sprenger L, Koelch MG, Groen G et al (2015). Neural correlates of successful psychotherapy of depression in adolescents. J Affect Disord 183: 239-246.
49. Tedesco V, Roquet RF, DeMis J, Chiamulera C, Monfils MH (2014). Extinction, applied after retrieval of auditory fear memory, selectively increases zinc-finger protein 268 and phosphorylated ribosomal protein S6 expression in prefrontal cortex and lateral amygdala. Neurobiol Learn Mem 115: 78-85.
50. Treit D, Pesold C, Rotzinger S (1993). Dissociating the anti-fear effects of septal and amygdaloid lesions using two pharmacologically validated models of rat anxiety. Behav Neurosci 107: 770-785.
51. Wiles N, Thomas L, Abel A, Ridgway N, Turner N, Campbell J et al (2013). Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 381: 375-384.
52. Yoshimura S, Okamoto Y, Onoda K, Matsunaga M, Okada G, Kunisato Y et al (2014). Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate cortex activity associated with self-referential processing. Soc Cogn Affect Neurosci 9: 487-493.